WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2002008179) ARYL SULFONAMIDES AS SEROTONIN ANTAGONIST FOR THE TREATMENT OF OBESITY
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2002/008179    International Application No.:    PCT/SE2001/001652
Publication Date: 31.01.2002 International Filing Date: 19.07.2001
Chapter 2 Demand Filed:    18.02.2002    
IPC:
A61K 31/18 (2006.01), A61K 31/4535 (2006.01), A61K 31/495 (2006.01), A61K 31/535 (2006.01), A61K 31/54 (2006.01), A61K 31/55 (2006.01), A61K 31/553 (2006.01), A61K 31/554 (2006.01)
Applicants: BIOVITRUM AB [SE/SE]; S-112 76 Stockholm (SE) (For All Designated States Except US).
CALDIROLA, Patrizia [IT/SE]; (SE) (For US Only).
JOSSAN, Sukhwinder [IN/SE]; (SE) (For US Only).
SAKARIASSEN, Kjell, S. [NO/SE]; (SE) (For US Only).
SVARTENGREN, Jan [SE/SE]; (SE) (For US Only)
Inventors: CALDIROLA, Patrizia; (SE).
JOSSAN, Sukhwinder; (SE).
SAKARIASSEN, Kjell, S.; (SE).
SVARTENGREN, Jan; (SE)
Agent: HÖGLUND, Lars; Biovitrum AB S-112 76 Stockholm (SE)
Priority Data:
0002739-1 21.07.2000 SE
Title (EN) ARYL SULFONAMIDES AS SEROTONIN ANTAGONIST FOR THE TREATMENT OF OBESITY
(FR) ARYLES SULFONAMIDES EN TANT QU'ANTAGONISTE DE LA SEROTONINE POUR TRAITER L'OBESITE
Abstract: front page image
(EN)The invention provides a method of treatment or prophylaxis of obesity, comprising administering to a patient in need of such treatment a therapeutically effective amount of an aryl sulfonamide compound of formula (I) or formula (II) wherein the substituents are as described in the specification in which E is -SO¿2?NH- or -NHSO¿2?.
(FR)L'invention concerne un procédé thérapeutique ou prophylactique de l'obésité consistant à administrer à un patient une quantité efficace sur le plan thérapeutique d'un composé d'aryle sulfonamide représenté par la formule (I) ou la formule (II), dans lesquelles les substituants correspondent à leur description énoncée dans la spécification et dans laquelle E représente -SO¿2?NH- ou -NHSO¿2?.
Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)